Related Experiment Video
Updated: Jun 14, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Exploring the Glycemic Control of Pay-for-Performance Program for Psychiatric Patients With Diabetes in Real World: A
Chin-Chou Yang1,2,3,4, Wen-Chen Ouyang5,6,7,8, Tsuo-Hung Lan1,9,10,11
1Tsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan.
None:
Background: Psychiatric patients with Type 2 diabetes often experience suboptimal care and poor health outcomes. Aims: This study is aimed at investigating the impact of a diabetes pay-for-performance (P4P) program on glycemic control in psychiatric patients with diabetes by comparing two regional psychiatric hospitals, one with the P4P program and one without. Methods: We conducted a retrospective quasiexperimental study. A total of 149 psychiatric outpatients with Type 2 diabetes were enrolled in the P4P group, and 129 patients were in the non-P4P group. Hemoglobin A1c (HbA1c) values in the fourth quarter of 2018 served as baseline (before P4P implementation in either hospital). Follow-up HbA1c levels were collected at 3, 6, 9, and 12 months in 2019. Propensity score matching was performed based on baseline HbA1c to create comparable groups. Changes in HbA1c over 1 year were analyzed using paired and independent t-tests and a generalized estimating equation (GEE) model. Result: The mean HbA1c level in the P4P group decreased progressively over 12 months (from 6.97% at baseline to 6.60%), whereas the non-P4P group showed an increase (from 7.00% to 7.12%). By the fourth quarter, the P4P group had a significantly lower mean HbA1c than the non-P4P group (p < 0.05). Subgroup analysis showed a greater HbA1c reduction in P4P participants who were male or had schizophrenia (p = 0.01 and p = 0.04, respectively). Conclusions: The P4P program was associated with significantly improved glycemic control in psychiatric patients with diabetes compared to usual care. This integrated care model may be an effective strategy to improve diabetes outcomes in psychiatric populations.
More Related Videos
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...

